Furthermore, research should focus on identifying specific biomarkers that, along with MUC1, could improve early diagnosis and management of CRSwNP, thus reducing the risk of progression to more severe forms and improving the Quality of Life (QoL) for patients. This evidence concerns the gene MUC1 and chronic rhinosinusitis with nasal polyps.